Uveal Neoplasms Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Uveal Neoplasms Epidemiology Forecast Report Coverage

Expert Market Research's “Uveal Neoplasms Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of uveal neoplasms. It projects the future incidence and prevalence rates of uveal neoplasms cases across various populations. The study covers age, gender, and type as major determinants of the uveal neoplasms population. The report highlights patterns in the prevalence of uveal neoplasms over time and projects future trends based on multiple variables.

Uveal Neoplasms Understanding: Disease Overview

Uveal neoplasms are tumors arising from the uveal tract, comprising the iris, ciliary body, and choroid. They can be benign (choroidal nevi, melanocytomas) or malignant (uveal melanoma, metastases). Uveal melanoma is the most common primary intraocular malignancy in adults, often presenting asymptomatically or with visual disturbances. Risk factors include fair skin, light eye color, and genetic predispositions. Early detection is critical, as malignant tumors can metastasize, primarily to the liver, significantly impacting prognosis and survival rates.

Uveal Neoplasms Epidemiology Perspective

The uveal neoplasms epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the uveal neoplasms epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for uveal neoplasms and their trends. The uveal neoplasms detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Uveal neoplasms represent all tumors of the uveal tract, with uveal melanoma accounting for 85 to 90 % arising from choroidal melanocytes, 3 to 5 % from the iris, and 5 to 8 percent from the ciliary body.
• The median age at UM diagnosis is approximately 62 years, with peak incidence observed between 70 and 79 years, highlighting a strong age-related susceptibility among older adults. It is unusual before age 40 and extremely rare in children, underscoring its link to long-term environmental and genetic influences.
• Males exhibit approximately 30% higher risk than females, reflecting a consistent male predominance across multiple population-based studies in the United States and Europe.
• In the U.S., non-Hispanic whites show the highest incidence (6.02 per million), whereas blacks and Asians have extremely low rates (0.31 and 0.39 per million, respectively).

Read more about this report - Request a Free Sample

Country-wise Uveal Neoplasms Epidemiology Segment

The uveal neoplasms epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, uveal neoplasms, predominantly uveal melanoma, demonstrate a stable but measurable incidence over several decades. The overall mean age-adjusted incidence from 1975 to 2020 was 5.6 per million population, reflecting its rarity. Notably, males exhibited a higher age-adjusted incidence of 6.3 per million, while females had an incidence of 5.0 per million. Although uncommon, ongoing surveillance and research remain crucial to improve early detection, management, and outcomes for affected individuals nationwide.

Uveal Neoplasms: Treatment Overview

Treatment depends on tumor size, location, and malignancy. Options include eye-preserving therapies such as plaque brachytherapy, proton beam therapy, laser photocoagulation, and transpupillary thermotherapy. Surgical interventions like enucleation are reserved for large or unresponsive tumors. Regular monitoring is essential for benign lesions to detect malignant transformation. Metastatic cases may require systemic therapies, including chemotherapy, immunotherapy, or targeted treatments. Multidisciplinary management optimizes ocular function preservation, reduces metastasis risk, and improves overall survival while maintaining quality of life.

Key Questions Answered

• What are the key findings of uveal neoplasms epidemiology in the 8 major markets?
• What will be the total number of patients with uveal neoplasms across the 8 major markets during the forecast period?
• What was the country-wise uveal neoplasms epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of uveal neoplasms during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of uveal neoplasms during the forecast period of 2026-2035?
• What are the currently available treatments for uveal neoplasms?
• What are the disease risks, signs, symptoms, and unmet needs of uveal neoplasms?

Scope of the Uveal Neoplasms Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of uveal neoplasms based on several factors.
• Uveal Neoplasms Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The uveal neoplasms report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Uveal Melanoma Drug Pipeline Analysis

Metastatic Uveal Melanoma Pipeline Analysis